To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Japan Approves Novoseven Coagulation Factor VIIa (Recombinant) For Hemophilia URL: http://www.pslgroup.com/dg/18F316.htm Doctor's Guide March 14, 2000
BAGSVAERD, DENMARK -- March 14, 2000 -- Novo Nordisk A/S announced that it has received approval from the Ministry of Health and Welfare in Japan to market NovoSeven(R) coagulation factor VIIa (recombinant). "This approval marks the completion of the initial registrations for NovoSeven in all the major markets and is an important milestone for us," says Lars Rebien Sorensen, corporate executive vice president, Novo Nordisk, Health Care. NovoSeven is a genetically engineered blood clotting protein that plays an important role in the sequence of events that normally leads to the formation of a clot in an injured blood vessel. NovoSeven is indicated for the treatment of bleeding episodes in hemophilia A and B patients with inhibitors (antibodies) to coagulation factors VIII or IX. The approval will not alter Novo Nordisk's financial expectations for 2000. Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore, the company is the world's largest producer of industrial enzymes. Headquartered in Denmark, Novo Nordisk employs approximately 15,200 people in 68 countries and markets its products in 179 countries. Its B shares are listed on the stock exchanges in Copenhagen, London and Zurich. Its ADSs are listed on the New York Stock Exchange under the symbol "NVO." A demerger of Novo Nordisk with the intention to spin off the Enzyme Business into a separately listed company is expected to take place around the turn of the year 2000/2001. Related Link: Novo Nordisk A/S. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.